Verastem Oncology submits NDA for ovarian cancer treatment

Verastem Oncology has concluded the rolling submission of a new drug application (NDA) to the US Food and Drug Administration (FDA) for a combination of avutometinib and defactinib for low-grade serous ovarian cancer (LGSOC).

Nov 3, 2024 - 06:00
Verastem Oncology submits NDA for ovarian cancer treatment
Verastem Oncology has concluded the rolling submission of a new drug application (NDA) to the US Food and Drug Administration (FDA) for a combination of avutometinib and defactinib for low-grade serous ovarian cancer (LGSOC).

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow